ES2196072T3 - Empleo de compuestos heterociclicos como ligandos de dopamina-d3. - Google Patents

Empleo de compuestos heterociclicos como ligandos de dopamina-d3.

Info

Publication number
ES2196072T3
ES2196072T3 ES95926896T ES95926896T ES2196072T3 ES 2196072 T3 ES2196072 T3 ES 2196072T3 ES 95926896 T ES95926896 T ES 95926896T ES 95926896 T ES95926896 T ES 95926896T ES 2196072 T3 ES2196072 T3 ES 2196072T3
Authority
ES
Spain
Prior art keywords
legandos
dopamina
employment
compounds
heterociclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926896T
Other languages
English (en)
Spanish (es)
Inventor
Beate Hellendahl
Annegret Lansky
Beatrice Rendenbach-Muller
Alfred Bach
Liliane Unger
Hans-Jurgen Teschendorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of ES2196072T3 publication Critical patent/ES2196072T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES95926896T 1994-07-15 1995-07-14 Empleo de compuestos heterociclicos como ligandos de dopamina-d3. Expired - Lifetime ES2196072T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4425146A DE4425146A1 (de) 1994-07-15 1994-07-15 Verwendung heterocyclischer Verbindungen

Publications (1)

Publication Number Publication Date
ES2196072T3 true ES2196072T3 (es) 2003-12-16

Family

ID=6523325

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926896T Expired - Lifetime ES2196072T3 (es) 1994-07-15 1995-07-14 Empleo de compuestos heterociclicos como ligandos de dopamina-d3.

Country Status (22)

Country Link
US (1) US6090807A (cs)
EP (1) EP0771197B1 (cs)
JP (1) JPH10502658A (cs)
KR (2) KR100443850B1 (cs)
CN (2) CN1152870A (cs)
AT (1) ATE236629T1 (cs)
AU (1) AU704839B2 (cs)
BG (1) BG63487B1 (cs)
BR (1) BR9508296A (cs)
CA (1) CA2195242A1 (cs)
CZ (1) CZ293126B6 (cs)
DE (2) DE4425146A1 (cs)
DK (1) DK0771197T3 (cs)
ES (1) ES2196072T3 (cs)
FI (1) FI970148A0 (cs)
HU (1) HUT77608A (cs)
MX (1) MX9700430A (cs)
NO (1) NO311683B1 (cs)
NZ (1) NZ290388A (cs)
PT (1) PT771197E (cs)
SI (1) SI9520084B (cs)
WO (1) WO1996002246A1 (cs)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69615376T2 (de) * 1995-07-13 2002-09-05 Knoll Gmbh Piperazin-derivate als heilmittel
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE69719191T2 (de) * 1996-05-11 2003-11-27 Smithkline Beecham P.L.C., Brentford Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
DE69704060T2 (de) * 1996-08-14 2001-08-02 Smithkline Beecham P.L.C., Brentford Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung
GB9708694D0 (en) * 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) * 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
TW530054B (en) * 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
ZA991315B (en) * 1998-02-20 2000-11-20 Ortho Mcneil Pharm Inc Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
ES2255311T3 (es) 1998-10-08 2006-06-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como moduladores de los receptores d3 de dopamina (agentes anti-psicoticos).
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
IT1314191B1 (it) * 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
US6365591B1 (en) 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
EP1272187B1 (de) * 2000-03-27 2008-07-30 Abbott GmbH & Co. KG Dopamin-d3-rezeptor-liganden zur behandlung von sucht
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
JP2005522436A (ja) * 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
DE10232020A1 (de) * 2002-07-04 2004-02-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Neurorezeptoraktive Heteroarencarboxamide
US20050197343A1 (en) * 2002-07-04 2005-09-08 Peter Gmeiner Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
WO2005058328A1 (en) 2003-12-18 2005-06-30 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
US8202868B2 (en) 2004-08-09 2012-06-19 Abbott Gmbh & Co. Kg 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2006072608A2 (en) * 2005-01-03 2006-07-13 Universitá Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
WO2006081289A2 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
WO2009095438A1 (en) * 2008-02-01 2009-08-06 Neurosearch A/S Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
WO2010040274A1 (zh) * 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
CN102482249B (zh) 2009-07-08 2016-06-08 德米拉(加拿大)公司 用于治疗皮肤病症或疾病状态的tofa类似物
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US20130289047A1 (en) * 2010-10-14 2013-10-31 Epiomed Therapeutics, Inc. Heteroarylthio derivatives and analogues
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
CN102408397B (zh) 2011-10-19 2014-08-20 上海贝美医药科技有限公司 紫杉烷类衍生物及其制备方法
US12338236B2 (en) 2022-01-29 2025-06-24 Suven Life Sciences Limited Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
DE1620016C3 (de) * 1966-07-02 1979-08-30 Merck Patent Gmbh, 6100 Darmstadt 3-{Piperazinoalkyl)-pyrazole und Verfahren zu ihrer Herstellung
DE2060816C3 (de) * 1970-12-10 1980-09-04 Merck Patent Gmbh, 6100 Darmstadt 4-Phenylpiperidinderivate Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen enthaltend diese Verbindungen
DE2110568A1 (de) * 1971-03-05 1972-09-07 Merck Patent Gmbh Neue N-Acyl-(piperazinoalkyl)-pyrazole
DE2213808A1 (de) * 1972-03-22 1973-09-27 Merck Patent Gmbh Verfahren zur herstellung von 3-(piperazinoalkyl)-pyrazolen
DE2258033A1 (de) * 1972-11-27 1974-05-30 Merck Patent Gmbh Verfahren zur herstellung von pyrazolderivaten
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
US4123529A (en) * 1976-04-23 1978-10-31 Lilly Industries Limited Phenylpiperazine derivatives
US4404382A (en) * 1980-09-17 1983-09-13 The Upjohn Company Piperazinyl-substituted imidazoles
US5254552A (en) * 1988-05-24 1993-10-19 American Home Products Corporation Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
FR2682953B1 (fr) * 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
HRP930210A2 (en) * 1992-02-25 1995-06-30 Recordati Chem Pharm Heterobicyclic compounds and pharmaceutical preparations containing them
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents

Also Published As

Publication number Publication date
KR100443850B1 (ko) 2004-08-11
CZ293126B6 (cs) 2004-02-18
KR20040000412A (ko) 2004-01-03
FI970148L (fi) 1997-01-14
NO970163D0 (no) 1997-01-14
BR9508296A (pt) 1998-05-19
WO1996002246A1 (de) 1996-02-01
SI9520084B (sl) 2005-02-28
AU3111495A (en) 1996-02-16
EP0771197A1 (de) 1997-05-07
BG63487B1 (bg) 2002-03-29
DK0771197T3 (da) 2003-06-23
HU9700111D0 (en) 1997-02-28
ATE236629T1 (de) 2003-04-15
CA2195242A1 (en) 1996-02-01
NO970163L (no) 1997-03-14
EP0771197B1 (de) 2003-04-09
CZ9697A3 (en) 1997-08-13
MX9700430A (es) 1998-05-31
SI9520084A (en) 1997-08-31
NZ290388A (en) 2001-04-27
KR970704435A (ko) 1997-09-06
AU704839B2 (en) 1999-05-06
JPH10502658A (ja) 1998-03-10
PT771197E (pt) 2003-08-29
DE4425146A1 (de) 1996-01-18
CN1534023A (zh) 2004-10-06
BG101112A (bg) 1998-04-30
FI970148A7 (fi) 1997-01-14
DE59510635D1 (de) 2003-05-15
US6090807A (en) 2000-07-18
CN1152870A (zh) 1997-06-25
HUT77608A (hu) 1998-06-29
NO311683B1 (no) 2002-01-07
FI970148A0 (fi) 1997-01-14

Similar Documents

Publication Publication Date Title
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
UY27884A1 (es) Moduladores del receptor de glucocorticoides
CR20120009A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
HN1999000080A (es) Derivados de isotiazol utiles como agentes anticancerosos.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
UY27918A1 (es) Derivados de benzodioxol
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2190430T3 (es) Nuevas sulfonamidas.
GT200000014A (es) Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
CO4560552A1 (es) Antagonistas de receptores de taquicininas no peptidicos
PA8601201A1 (es) Ligandos del receptor cannabinoide y usos de los mismos
CL2004000861A1 (es) Compuesto biciclico derivado de pirazol [4,3-d] pirimidin-7-ona o de pirazol [4,3-c] piridin-7-ona de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al comp
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
GT199900189A (es) Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña.